Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T12:50:54.090Z.
Calculation as of: 2026-10-06T12:50:54.090Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cf0630fc9642b75147419b140bafddb7ccff0a2362c2d95f2dd7172ee2000ae5
EARNINGS YIELD
N/A
Market Cap
$922.50M
Earnings Yield
16.71%
TTM Avg
17.36%
3Y Avg
17.36%
5Y Avg
17.36%
Market Cap
$921.45M
Earnings Yield
2.27%
TTM Avg
2.73%
3Y Avg
2.26%
5Y Avg
1.85%
Market Cap
$903.13M
Earnings Yield
N/A
TTM Avg
2.57%
3Y Avg
2.57%
5Y Avg
2.57%
Market Cap
$985.79M
Earnings Yield
N/A
TTM Avg
17.88%
3Y Avg
17.88%
5Y Avg
17.88%
Market Cap
$867.60M
Earnings Yield
N/A
TTM Avg
2.16%
3Y Avg
2.16%
5Y Avg
2.16%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CeriBell, Inc. (CBLL) | $943.26M | N/A | N/A | N/A | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $922.50M | 16.71% | 17.36% | 17.36% | 17.36% |
| HealthStream, Inc. (HSTM)vs › | $921.45M | 2.27% | 2.73% | 2.26% | 1.85% |
| Bioventus Inc. (BVS)vs › | $915.95M | 5.70% | 3.29% | 3.29% | 3.62% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | N/A | 2.57% | 2.57% | 2.57% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | N/A | 17.88% | 17.88% | 17.88% |
| Aktis Oncology, Inc. (AKTS)vs › | $989.05M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | N/A | 2.16% | 2.16% | 2.16% |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | N/A | 2.18% | 3.28% | 2.72% |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
